IVVD logo

INVIVYD INC

IVVDNASDAQ
🏆 #3664 by market capUS Equity
$0.61—
Last available close · quote unavailable
🔔
Track IVVD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 1.4%
14d▼ 8.1%
30d▼ 27.7%
ytd▼ 75.2%
1y▼ 67.7%
🏦Market Cap
$177M
Small Cap
📈Revenue Growth (YoY)
110.5%
High Growth
📊Gross Margin
91.3%
High
💵FCF Margin
-187.9%
Thin
⚖️P/S Ratio
3.0x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$0.53 – $3.07
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
294.8M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$53M
Last Q Revenue
$14M
P/E Ratio
-1.5
P/S Ratio
3.0x
EPS (TTM)
$-0.33
Dividend Yield
0.00%
Dilution (1yr)
+45.3%
IVVD logo

INVIVYD INC

IVVD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53M▲ +110.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.0%▼ −0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$56M▼ −68.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$58M▼ −65.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
172.2M▲ +45.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$224M▲ +$156M YoY
StockOtter · stockotter.space

About INVIVYD INC

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.